Zennova Pharma Completes Nearly CNY 100 Million Series B Financing, with T-Capital as Financial Advisor

Recently, Zennova Pharma Group has completed its Series B financing of nearly CNY 100 million, with T-Capital acting as the financial advisor for this round.

This financing round is a significant capital operation for Zennova Pharma to continue advancing its innovative drug R&D and business development. By bringing in capital resources, the company will further support the progression of its R&D pipeline and related business layouts.

Project Overview

Zennova Pharma is a pharmaceutical company focused on the R&D of innovative drugs, with its business covering therapeutic areas such as ophthalmology, anti-tumor, anti-virus, and cardiovascular.

According to information previously disclosed by T-Capital, Zennova Pharma completed a Series A financing of tens of millions of CNY in 2021, with T-Capital also serving as the financial advisor for that round. This Series B financing further demonstrates the company’s ability to continuously obtain capital support during its R&D and business development stages.

Key Information of This Transaction

Item	Information
Company	Zennova Pharma Group
Financing Round	Series B
Financing Size	Nearly CNY 100 Million
Industry	Biopharma
Key Focus	Innovative Drug R&D
Financial Advisor	T-Capital

Focusing on Innovative Drug R&D and Commercialization

The financing needs of healthcare companies are typically closely related to their R&D cycles, product pipelines, and commercialization progress.

For innovative drug companies, from early-stage R&D to clinical development, registration filing, and commercialization, continuous investment in R&D funds is required, as is the constant adjustment of capital and strategic resource allocation at different stages.

Zennova Pharma’s previously completed Series A financing was mainly used to accelerate the company’s drug development in the fields of ophthalmology, anti-tumor, anti-virus, and cardiovascular. The completion of this Series B financing provides new capital support for the company to further advance its R&D and business development.

From the perspective of corporate development, continuous financing is not only a supplement of funds but can also be an important way for a company to allocate resources during R&D advancement, talent acquisition, industrial cooperation, and future commercialization.

From Series A to B: Continuous Capital Support for the R&D Pipeline

For innovative drug companies, the progression of financing rounds is often related to the company’s R&D stage and changing capital needs.

Early-stage financing mainly solves problems such as technology development, core team building, and R&D pipeline advancement. As the company enters deeper R&D stages, the funding demand usually increases further, and financing needs to be matched with clinical development, registration filing, and subsequent commercialization planning.

Zennova Pharma previously completed a Series A financing of tens of millions of CNY, with the funds mainly used to advance drug development in the fields of ophthalmology, anti-tumor, anti-virus, and cardiovascular. Subsequently, the company has now completed a Series B financing of nearly CNY 100 million.

This financing path reflects the continuous demand for capital resources of innovative drug companies at different stages of development.

T-Capital Acted as the Financial Advisor for This Round

In this financing, T-Capital acted as the financial advisor to Zennova Pharma, participating in the capital market and transaction advisory work during the company’s financing process.

T-Capital has long focused on the healthcare sector, providing advisory services such as equity financing, M&A and restructuring, divestitures, licensing and joint ventures, and cross-border transactions for biopharmaceuticals, medical devices, medical diagnostics, high-value consumables, healthcare services, and other healthcare companies.

To date, T-Capital has served hundreds of healthcare companies in areas including new drug R&D, medical devices, medical diagnostics, high-value consumables, healthcare services, and emerging technologies.

For innovative drug companies, the work of a professional financial advisor includes not only connecting financing resources but also multiple aspects such as financing strategy, investor screening, transaction communication, valuation analysis, and financing process management.

Healthcare Corporate Finance Increasingly Focuses on Long-Term Value

Innovative drug R&D is characterized by long development cycles, large capital investment, and high technological uncertainty.

Therefore, healthcare corporate financing usually requires comprehensive consideration of:

The company’s core technology and product pipeline;
R&D stage and clinical progress;
Intellectual property and technical barriers;
Market space and competitive landscape;
Future commercialization potential of the pipeline;
The company’s future funding needs;
The industrial resources and strategic synergy capabilities of investors.

For companies at different stages of development, their financing strategies also need to be adjusted accordingly.

From Series A to Series B, and to subsequent financing or capital market exits, companies need to gradually establish a capital strategy that matches their R&D stage and commercialization goals.

T-Capital: Continuously Serving the Capital Needs of Healthcare Companies

The Zennova Pharma project is one of T-Capital’s cases of serving the financing needs of healthcare companies.

Previously, T-Capital also acted as the financial advisor for Tongyi Biopharma’s Series B and B+ financing rounds. In 2023, Tongyi Biopharma announced the consecutive completion of its Series B and B+ financing rounds, raising nearly USD 100 million, with the funds mainly used to advance the clinical development of its pipeline related to the Bi-specific ligand-drug Conjugate (Bi-XDC) technology platform.

T-Capital continues to focus on innovative drugs, biopharmaceuticals, medical devices, and other healthcare sub-sectors, providing financing and strategic transaction advisory services for companies at different stages of development by connecting capital and industrial resources.

Project Keywords

About T-Capital

T-Capital is a consulting firm focused on the broad healthcare sector, providing advisory services such as equity financing, M&A and restructuring, divestitures, licensing and joint ventures, and cross-border transactions.

The firm focuses on healthcare companies with technological or business model innovations, serving areas including new drug R&D, medical devices, medical diagnostics, high-value consumables, healthcare services, emerging technologies, and consumer health.

T-Capital is committed to connecting capital with healthcare companies, as well as domestic with international resources, to find funding, technology, and industrial partners for companies, supporting them in achieving long-term value at different stages of development.

Equity Financing Advisory
Healthcare Corporate Finance
M&A and Divestiture Transactions
Licensing and Strategic Cooperation
Cross-Border Healthcare Transactions
Healthcare Corporate Capital Strategy Consulting

To learn more about the services T-Capital provides for healthcare companies in financing, M&A, and strategic transactions, please visit Our Services or Contact Us.

[T-Capital Deal] Zennova Pharma Completes Nearly CNY 100 Million Series B Financing, with T-Capital as Financial Advisor